Roche's Boniva to get generic competition; Pfizer's arthritis treatment moves toward approval;

 @FiercePharma: Derek Lowe's take on the GSK-won't-buy-AstraZeneca story. Hint: Fig Newtons figure in. More | Follow @FiercePharma

 @EricPFierce: FDA says drugs shortages are down dramatically. Commissioner gives president credit. Really? Report | Follow @EricPFierce

> Indian genericsmaker Dr. Reddy's says it has received FDA approval to produce a knock-off of Roche's osteoporosis drug Boniva. Story

> The upside of Regeneron Pharmaceuticals' ($REGN) Arcalyst may not be enough to offset the risk of side effects, FDA staff reported today. Story

> Analysts are predicting Pfizer's ($PFE) experimental treatment for rheumatoid arthritis will get regulatory approval next week despite some significant risks. Story

> FDA orders Alexza Pharmaceuticals ($ALXA) to fix manufacturing issues before it will approve its NDA for Adasuve, a schizophrenic and bipolar disorder treatment. Story

> In a twist on the usual pharma deal, Affymetrix will actually pay $15 million less than its initial bid of $330 million in the buyout of eBionscience.  Story

Biotech News

 @FierceBiotech: Startup Bina Technologies tries Apple-like strategy in genomics field. Item | Follow @FierceBiotech

 @JohnCFierce: Big week for Pfizer coming up, with tofacitinib panel. They need a win here to regain some R&D cred. Story | Follow @JohnCFierce

 @RyanMFierce: Fumapharm AG shareholders take early payday on BG-12 interest in $761M Royalty Pharma deal. Release | Follow @RyanMFierce

 @MarkHFierce: Scientists have identified a gene linked to a rare condition where babies are born minus a spleen. Release | Follow @MarkHFierce

> Bill calls for cancer clinical trials results to be reported--or else. News

> FDA whacks Alexza Pharma with CRL for Adasuve. Story

> Pfizer faces crucial panel vote on blockbuster hopeful tofacitinib. Article

Medical Devices News

 @FierceMedDev: U.K. regulators toughen focus against counterfeit devices and drugs. More | Follow @FierceMedDev

> Qiagen snatches up maker of amniotic fluid detection test. News

> Retinal implants yield amazing results in U.K., China. More

> (Lack of) FDA device monitoring draws new scrutiny. Article

> U.K. regulators toughen focus against counterfeit devices and drugs. Story

And Finally... AstraZeneca's ($AZN) exiting CEO David Brennan may be a $65 million example of the Peter Principle, says the health blog. Post

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.